Portfolio Lab

Rigel Pharmaceuticals Inc

  • Stock
  • Ticker RIGL
  • ISIN US7665597024
  • Nasdaq

Health care · Pharmaceuticals · USA

$40.09 −2.67%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Rigel Pharmaceuticals Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

RIGLGlobal equities (VT)

$10,000 grew to $14,267. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −86.4% in 11/2022, measured from the peak in 02/2021. It took 57 months to get back to the old peak.

1-year return
−8.6%
5-year return p.a.
+5.6%
10-year return p.a.
+3.6%
Volatility p.a.
84.0%
Largest decline
−86.4%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue58531026970597981
Gross profit5249976564547070
Operating income1713612823122417
EBITDA1713622924122419
Net income141160282688.71713
Earnings per share0.810.633.281.4614.100.440.880.65
Balance sheet
Total assets164176207243514505521524
Liabilities1611571251251221059679
Equity3.31982118391400425445
Cash5746534941246147
Long-term debt606060605345––
Cash flow
Operating cash flow15-0.93124222.73135
Free cash flow15-0.93124222.73135

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +154.6%, weakest 2022 at −43.4%. 4 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026$0.65
4 Aug 2026$0.88
5 May 2026$0.44
3 Mar 2026$14.10
4 Nov 2025$1.46
5 Aug 2025$3.28
6 May 2025$0.63
4 Mar 2025$0.81
7 Nov 2024$0.70
6 Aug 2024−$0.06
7 May 2024−$0.47
5 Mar 2024$0.05

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€684m
Market cap in trading currency
$755m
Enterprise value
$656m
P/E
2.5
P/S
2.62
P/B
1.70
EV/Sales
2.27
EV/EBITDA
8.2
Earnings yield
40.1%
FCF yield
11.9%

Results (last four quarters)

Revenue
$288m
Gross profit
$258m
EBITDA
$79.6m
Net income
$307m
Earnings per share
$16.07
Revenue per share
$15.31
Revenue growth
+16.5%
Earnings growth
−52.7%

Profitability

Gross margin
89.6%
Operating margin
26.3%
Net margin
106.6%
Return on equity
109.2%
Return on assets
58.6%

Balance sheet and cash flow

Cash
$99.3m
Cash per share
$5.27
Financial debt
–
Debt/equity %
–
Current ratio
2.39
Book value per share
$23.64
Operating cash flow
$89.9m
Free cash flow
$89.9m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
18.8m
Volume
352,027
Avg. volume 3 months
254,159
Relative volume
1.4

Price and technicals

Price
$40.09
1 day
−2.7%
52-week high
$51.45
52-week low
$25.44
Distance to 52-week high
−22.1%
Distance to 52-week low
+57.6%
Distance to 50-day line
−14.5%
Distance to 200-day line
+6.2%
RSI (14)
35
Volatility 1M
76.7%

Performance

1 week
−9.8%
1 month
−17.9%
3 months
−11.1%
6 months
+38.2%
YTD
−6.4%
1 year
−3.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has RIGL performed since 11/2016?

$10,000 grew to $14,267 by 20 Nov 2026, which is +3.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is RIGL?

Volatility was 84.0% per year, measured on monthly returns. The largest decline from a peak was −86.4%, with the low in 11/2022.

How does RIGL compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, RIGL returned +3.6% at 84.0%. The correlation of monthly returns was 0.28; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Rigel Pharmaceuticals Inc (RIGL): Return and risk